Ask AI
ProCE Banner Activity

International Perspectives on Developments and Decision-making Tools for Frontline Treatment of CLL/SLL

Clinical Thought

Read this commentary to gain insight into the latest approvals and data for previously untreated chronic lymphocytic leukemia and access our interactive decision support tool with recommendations from 5 international experts for specific patient case scenarios.

Released: February 17, 2026

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by an educational grant from AstraZeneca.

AstraZeneca

Target Audience

This activity is intended for global hematologists, medical oncologists and other healthcare professionals involved in the treatment of patients with CLL.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Assess approved frontline BTK inhibitors considering binding, targeted selectivity, global indications, dosing, safety profile, and efficacy

  • Develop individualized, BTK inhibitor–based therapeutic strategies for treatment-naive patients with CLL/SLL that reflect current clinical trial data, expert insights, and evolving global treatment recommendations, including considerations for both continuous and fixed-duration regimens

Disclosure

Primary Author

Stephen Stilgenbauer, MD: consultant/advisor/speaker: AbbVie, Amgen, AstraZeneca, BeiGene, Bristol Myers Squibb, Galapagos, Gilead, GSK, Hoffmann-La Roche, Johnson & Johnson; researcher: AbbVie, Amgen, AstraZeneca, BeiGene, Bristol Myers Squibb, Galapagos, Gilead, GSK, Hoffmann-La Roche, Johnson & Johnson.